Filter by Year: ALL 2022 2021 2020 2019 2018 2017 2015 Source PharmaVoice Foghorn's CEO on why collaborations are key to unlocking precision medicine January 28, 2022 Source GEN News New Cancer Treatments Lead to New Strategic Options January 5, 2022 Source Endpoints Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal December 13, 2021 Source Bloomberg Lilly Joins Foghorn in $380 Million Pact for Genetic Cancer Treatments December 13, 2021 Source MedCityNews Eli Lilly steers into Foghorn’s gene traffic control drugs with $380M pact in cancer December 13, 2021 Source FierceBiotech Eli Lilly puts $1.3B in biobucks on the line for Foghorn's oncology programs December 13, 2021 Source Targeted Oncology Treatment With FHD-609 Begins in Phase 1 Synovial Sarcoma Study August 23, 2021 Source PharmaVoice CMO Sam Agresta Named to PharmaVOICE 100 August 1, 2021 Source BioSpace Q&A: Foghorn SVP Expounds on "Tremendous Opportunity" in Chromatin Remodeling April 20, 2021 Source XCONOMY Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck July 8, 2020 Previous 1 2 3 4 Next